BC
MDGL icon

Brookfield Corp’s Madrigal Pharmaceuticals MDGL Stock Holding History

Brookfield Corp’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-3,075
Closed -$220K – 719
2022
Q2 		$220K Buy
+3,075
New +$226K ﹤0.01% 556

Other funds holding MDGL

ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Brookfield Corp's MDGL Position: Q3 2022 in Review

Brookfield Corp sold out of Madrigal Pharmaceuticals (MDGL) in Q3 2022, closing a stake of 3,075 shares — an estimated $220K sold.

Brookfield Corp first reported a position in MDGL in Q2 2022 and held it in 1 quarter. The position peaked at $220K in Q2 2022. 135 funds tracked by Wall St. Rank hold MDGL as of Q3 2022.

  • Brookfield Corp reported no remaining Madrigal Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
  • Brookfield Corp sold 3,075 Madrigal Pharmaceuticals shares in Q3 2022, an estimated $220K.
  • Brookfield Corp first reported a position in Madrigal Pharmaceuticals in Q2 2022 and held it in 1 quarter.
  • Brookfield Corp's Madrigal Pharmaceuticals position peaked at $220K in Q2 2022.
  • 135 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q3 2022.

Based on Brookfield Corp's 13F filing for Q3 2022, filed 14 Nov 2022.